cyrilzakka/clinical-trials huggingface dataset:
Prostate Hypoxia - TIC

Prostate cancer is the most commonly diagnosed form of cancer in Canadian men. In 2006, greater than 250,000 men were diagnosed with prostate cancer in the United States and Canada with more than 32,000 men dying of their disease. Using the prognostic variables of T-category, the serum prostate specific antigen (PSA), and the pathologic Gleason score (GS), men with localized prostate cancer are placed in low, intermediate and high-risk groupings. Usually this is treated with surgery, radiation therapy, hormone therapy and/or watchful waiting (also known as active surveillance). While these treatments are quite effective, tumours are likely to recur in about 40% of cases. There is a need for additional prostate cancer treatments. To address this need, many experimental therapies are being developed and tested in mice with prostate tumors. This includes the study of aggressive prostate cancer cells such as stem cells, or Tumour Initiating Cells (TICs), or oxygen deprived cells, which may be the ones most likely to re-grow into a tumour or spread throughout the body. Researchers want to try and isolate these special cells from the prostate after surgery to study their features, and to see if they can re-grow as solid tumours in mice. Researchers would like to test whether the prostate cancer stem cells are more resistant or less resistant to treatments. This will allow researchers to study and test new treatments that specifically target resistant and aggressive prostate cancer cells. The investigators hypothesize that marker-defined TIC cells or hypoxic cancer cells have unique genetics in primary prostate cancers and are relatively chemo- and radio-resistant.


Eligibility Criteria:
Inclusion Criteria:

* Prostate cancer patients with bulky intermediate risk or high-risk disease who have already agreed to undergo an open radical prostatectomy at Princess Margaret Cancer Centre-UHN:
* Clinical stage T2-T3 N0 M0
* Pathology of adenocarcinoma of the prostate AND
* Gleason score 7 with \>/= 50 % biopsies involved with tumour; OR
* Gleason score 8 or above (any percentage of biopsies)

Exclusion Criteria:

* Patients with clinical T4, N1 or M1 disease
* Patients with histologies other than adenocarcinoma
* Patients unable to ingest pimonidazole tablets
A Resilience Building Intervention to Promote Successful Aging

In this pilot study, a pre-post experimental design will be used, in which 60 community dwelling adults aged 50+ will recruited from a larger parent study, and will then be randomized to either a no-contact control or intervention condition. Those in the intervention condition will receive a psychoeducational intervention in which they will receive scientific literature-based information on resilience and strategies to bolster resilience, as well as developing an individualized plan on areas to engage in at home over the next four weeks. All participants will return for an immediate posttest using an abbreviated version of the baseline battery from the parent study.


Eligibility Criteria:
Inclusion Criteria/Exclusion Criteria:

* Must be enrolled in a larger parent study
* The criteria for the parent study are: no neurological or severe neuromedical disorders (e.g., stroke, schizophrenia), must be able to speak English, not be legally blind or deaf, not currently undergoing chemotherapy or radiation therapy, no brain trauma with loss of consciousness greater than 30 mins, and not homeless.
Aggrenox Prevention of Access Stenosis

The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.


Eligibility Criteria:
Inclusion criteria:

* Age 18-21 depending on state regulations
* Life expectancy of at least six months
* Chronic renal failure with anticipated start of hemodialysis within six months of enrollment, or current dialysis dependence
* A new or planned arteriovenous (AV) graft placed in any location for the purpose of hemodialysis. (Any type of graft material and any configuration of the access is acceptable).
* The patient is expected to stay at a participating dialysis facility for at least 6 months.
* The patient's physician(s) will allow the patient to participate.
* Ability to give informed consent.

Exclusion Criteria:

* Women must not be pregnant, breastfeeding, or plan to be pregnant during the course of the study.
* The presence of ongoing bleeding.
* The presence of a known bleeding disorder (e.g., hemophilia or von Willebrand's disease).
* Recent bleeding episode requiring transfusion within 12 weeks of entry.
* The presence of acute ulcer disease. Acute ulcer disease is defined as a new diagnosis of peptic disease including esophagitis, gastritis, or ulcer or the initiation of treatment with proton pump inhibitors, H2 blockers or therapy for Helicobacter pylori within three months prior to obtaining consent.
* Known allergy or adverse reaction to Aggrenox or any of its study components (dipyridamole and aspirin).
* Required use of warfarin, dipyridamole, non-steroidal antiinflammatory drugs or other antiplatelet agents other than aspirin.
* Current uncontrolled hypertension with systolic blood pressure in excess of 200 mm Hg or diastolic blood pressure in excess of 115 mm Hg.
* Baseline platelet count less than 75,000/mm3.
* Known advanced liver disease with decompensated cirrhosis, jaundice, ascites or bleeding varices.
* Current problem with substance abuse.
* Concurrent participation in another medical intervention trial.
* Anticipated non-compliance with medical care based on physician judgment.
* Patient refusal.
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

This study will evaluate the hypothesis that the administration of intraventricular tPA reduces the rates of cerebral vasospasm and ventriculoperitoneal shunt-dependent hydrocephalus in patients with aneurysmal subarachnoid hemorrhage.


Eligibility Criteria:
Inclusion Criteria:

* Age greater than 18 years old.
* SAH due to aneurysm, as determined by CT angiogram or cerebral angiogram.
* Modified Fisher (mF) grade 3 or 4 SAH, defined as thick cisternal blood without (grade 3) or with (grade 4) intraventrciular blood.
* Exclusion of the aneurysm from the parent circulation by endovascular embolization (Raymond class I or II) within 48 hours of ictus.
* Ventriculostomy placement must occur prior to randomization.
* Informed consent obtained from the patient or patient's decision maker

Exclusion Criteria:

* Determination by treating physician(s) that no ventriculostomy is needed.
* Presence of intrinsic clotting disorders (e.g. due to hepatic failure, nephrotic syndrome, etc). Subjects whose pharmacologic anticoagulation is reversed, as determined by PT/INR, PTT within our institution's normal range, will be permitted to participate in this study.
* Presence of significant anemia, defined as hemoglobin \< 8 gm/dL.
* Patients who undergo endovascular techniques requiring post-operative dual anti-platelet therapy.
* Residual aneurysm sac filling (Raymond class III occlusion).
* Aneurysm or vessel perforation during the endovascular procedure.
* Presence of craniectomy.
* Significant neurologic disability prior to the onset of SAH.
* Determination that administration of tPA/placebo cannot be initiated within 72 hours of symptom onset.
* Presence of untreated intracranial aneurysms larger than 3mm on CT angiography or cerebral angiogram.
Genicular Radiofrequency Ablation Versus Pulsed Radiofrequency

This study investigates the effectiveness of two treatments-genicular nerve radiofrequency ablation and pulsed radiofrequency-in reducing pain and improving function in osteoarthritis patients. These techniques, used after diagnostic nerve blocks, aim to provide long-lasting pain relief. Despite both being found effective, no clear consensus exists on which method is superior. The study seeks to compare these techniques and contribute new insights to the existing literature.

Chronic knee pain, especially in osteoarthritis patients, is a common condition that significantly affects mobility and quality of life. In individuals over the age of 60, the incidence is 9.6% in men and 18% in women. In patients with osteoarthritis, weight loss and appropriate exercises are recommended as the primary treatments. This is followed by medical therapy, injection treatments, and, if necessary, total knee arthroplasty. However, for patients with a body mass index (BMI) of 40 or higher, total knee arthroplasty is avoided due to the high surgical risk. In recent years, genicular nerve diagnostic block and radiofrequency ablation have been shown to reduce pain and improve function in these patients . Radiofrequency ablation works by blocking the transmission of sensory nerves, thereby improving function.

The innervation of the knee joint originates from the femoral nerve's articular branches, the common peroneal, saphenous, tibial, and obturator nerves. These articular branches are known as the genicular nerves, which are superficial and can be easily accessed using both fluoroscopy and ultrasound.

In osteoarthritis patients, superior medial, superior lateral, and inferior medial genicular nerve blocks are applied. After the diagnostic block, some clinics apply radiofrequency thermocoagulation to the genicular nerve branches for a lasting effect, while others use pulsed radiofrequency. Both techniques have been found to be effective, but there is no data in the literature regarding which technique is superior. The aim of this study is to determine which of the two techniques is more effective and share the findings with the literature.

Eligibility Criteria:
Inclusion Criteria:

* patients over the age of 18
* osteoarthritis
* Grade 2-4 gonarthrosis according to the Kellgren-Lawrence (KL) classification
* Pain 6-10 on the Numeric Rating Scale (NRS)

Exclusion Criteria:

* Patients with chronic knee pain due to another pathology (e.g., meniscopathy, trauma, rheumatoid arthritis) History of previous knee surgery History of intra-articular injection in the last 3 months Coagulopathy, use of antiplatelet or anticoagulant medications Infection Severe psychiatric disorders Patients with a cardiac pacemaker or defibrillator Renal or hepatic failure
Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy

Prevalence of chronic pain after mastectomy is beyond 50% 3 months after surgery. This pain is related to a sensitization of the central nervous system through N-methyl-D-asparate (NMDA) receptors. Ketalar might prevent the occurrence of chronic pain by anti-NMDA properties after mastectomy.


Eligibility Criteria:
Inclusion Criteria:

* Mastectomy in patients 18 to 80 years old

Exclusion Criteria:

* American Society of Anesthesiology (ASA) class \>= 3
* Renal, heart or hepatic failure
* Allergy to ketalar
* Psychiatric disease
* Chronic antalgic treatment
Ga68 V/Q PET/CT for Pulmonary Embolism Diagnosis: a Diagnostic Accuracy Study Vs CT Pulmonary Angiography

This study evaluates the diagnostic accuracy (sensitivity, specificity) of V/Q PET/CT for the diagnosis of pulmonary embolism (PE), using CT pulmonary angiography as a reference standard.

V/Q PET/CT imaging is now possible by substituting 99mTc with 68Ga, a positron-emitting radionuclide, using the same carrier molecules as conventional V/Q imaging. Ventilation imaging can be performed with 68Ga-carbon nanoparticles using the same synthesis device as Technegas. Perfusion imaging can be performed with 68Ga-macroaggregated albumin (68Ga-MAA).Technical advantages of PET compared to SPECT include higher sensitivity, higher spatial and temporal resolution and superior quantitative capability. This offers the opportunity to improve the accuracy of V/Q imaging in patients with suspected PE, while decreasing the acquisition time.

The aim is to perform a formal diagnostic accuracy study of V/Q PET/CT for PE, using CTPA as a reference standard.

Patients with suspected acute PE undergo CTPA and V/Q PET/CT imaging within 24 hours.

V/Q PET/CT images are not used for patients management.

After completion of inclusion, central readings of scans will be conducted independently.

Eligibility Criteria:
Inclusion Criteria:

* Patient with suspected first episode of acute PE,
* Age ≥ 18 years .
* Insured patient.

Exclusion Criteria:

* Patients with a clinically suspected massive PE.
* Contraindication to contrast media (including renal insufficiency with creatinine clearance \< 30 ml/min).
* Inability to perform CTPA and V/Q PET/CT within 24 hours.
* History of deep vein thrombosis or PE
* Unable/unwilling to give informed consent.
* Pregnancy / breast-feeding.
* Patient under guardianship or curatorship
A Comparison of Two Different Treatment Approaches for Adolescents With Osgood Schlatter

The most common growth-related injury is Osgood Schlatter, which affects up to 1 in 5 physically active adolescents. It can cause long-term pain and potential discontinuation of sports and physical activity, with sequela well into adulthood. No effective conservative treatments have been documented, and clinical practice is characterized by a wealth of conflicting advice and modalities. A novel treatment approach has shown promising results in a small single-cohort study. Therefore, this study aims to compare this novel treatment with usual care in 10-16-year-old adolescents with Osgood Schlatter.

This single-center pragmatic, double-blinded, randomized, controlled superiority trial, will have a two-group parallel arm design. Participants will undergo 3 months of treatment, followed by 2 months of self-management with self-reported knee function (KOOS-child 'Sport/rec') at 5 months as the primary endpoint.

This trial comparing a novel treatment with usual care for adolescents with Osgood Schlatter could result in an evidence-based treatment ready for implementation in clinical practice, benefitting patients outcomes and clinicians.


Eligibility Criteria:
Inclusion Criteria:

* Tenderness on palpation of the tibial tuberosity or pain during resisted isometric knee extensions
* Insidious onset of pain or swelling of the tibial tuberosity for ≥6 weeks
* Provoked by at least 2 of the following positions or activities; prolonged sitting or kneeling, squatting, running, hopping/jumping, stair walking or during multidirectional sports
* Clinical diagnosis of Osgood Schlatter
* Markedly reduced sports participation OR severely affected by pain during sports participation

Exclusion Criteria:

* Other primary pathology or complaints from other structures of the knee
* Other injuries, complaints or illnesses that may cause disability, or specifically restricts levels of physical activity or sports participation
* Previous surgery in the lower extremities or lumbar spine
* Congenital deformities, device implants og cysts og tumors of the knee
* Participants not willing to cease concomitant treatment
* Participants and their parents not able to understand and communicate in written and verbal Danish
Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles

The study was designed to investigate the effect of luteal-phase administration of gonadotrophin releasing hormone agonist(GnRHa) on pregnancy outcomes in in-vitro fertilization-embryo transfer.


Eligibility Criteria:
Inclusion Criteria:

1. Age \< 37 years;
2. One or more high quality embryos have been got in IVF/ICSI treatment;
3. To transfer at lest 2 fresh embryos;
4. Uterine endometrial thickness ≥ 7mm;
5. Patients have signed informed consents.

Exclusion Criteria:

1. ≥3 IVF/ICSI/FET cycles and no pregnancy;
2. Polycystic ovary syndrome(PCOS);
3. uterine malformation;
4. endometriosis
5. patients with a history of recurrent pregnancy loss.
Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia

Androgenic alopecia is the most common cause of hair loss in men. Finasteride and minoxidil are available in treatment of androgenetic alopecia, although the former causes decreased libido or ejaculate volume, erectile dysfunction, the latter causes scaling, itching of the scalp. Recently, Pulpkin Seed Oil shows some improved clinical efficacy on scalp hair growth in men with androgenetic alopecia, but there is no evidence to support this.

The investigators conducted a randomized, double-blind, placebo-controlled efficacy and tolerability trial of Pumpkin seed oil (400mg/day)therapy in male patients with androgenetic alopecia.


Eligibility Criteria:
Inclusion Criteria:

* 18 to 65 years of age
* Androgenetic alopecia of Norwood-Hamilton scale grade II-V

Exclusion Criteria:

* Severe medical problems including renal problems, prostate diseases, diabetes mellitus o
* Patients who took any medicine which can affect the hair growth in recent 3 months.
Yoga as an Intervention for Women With Knee Osteoarthritis

Keeping individuals with knee osteoarthritis physically active is critically important. Exercise is effective at reducing pain while improving physical function. However some exercises can overload the knee, and as a result, worsen knee pain and health of the knee joint. Yoga offers a foundation of static postures that improve muscle strength and joint flexibility. Using sophisticated technology that allows us to calculate the loads inside the knee, the investigators have selected yoga exercises that do not overload the knee joint. The investigators have designed a yoga exercise class that is ideal for people with knee osteoarthritis. The purpose of the study is to investigate whether these yoga exercises increase muscle strength and reduce knee pain in women with knee osteoarthritis. In addition, the investigators aim to show that these yoga exercises will also improve knee loads during activities, mobility and heart health. The investigators will ask 50 women with knee osteoarthritis to participate in a 12 week yoga exercise intervention, that requires attendance to 3 classes each week. The investigators will test strength of the leg muscles, pain, knee joint loads, mobility and cardiovascular health before and after the 12 week yoga exercise intervention.

This study is an uncontrolled intervention study with repeated measures. The intervention is a 12-week supervised exercise class featuring biomechanically sound exercises for people with knee osteoarthritis. Measures of strength of the knee muscles, pain, biomechanics during walking and yoga, mobility and cardiovascular health will be included. Strength will be measured on a dynamometer. Pain will be assessed with questionnaires. Walking and three yoga postures will be observed using motion capture system integrated with force measurements from the floor. Mobility will be assessed during walking, stair-climbing and chair standing tasks. Cardiovascular health will be measured during a submaximal bicycle task.

Eligibility Criteria:
Inclusion Criteria:

* Female - 50 years of age or older
* Knee pain on most days of the week
* Less than 30 minutes of morning stiffness
* Bony enlargement
* Bony tenderness to palpation
* Signs of inflammation
* Able to safely climb 2 flights of stairs without aid
* Visited a family physician within the last 12 months

Exclusion Criteria:

* Any other forms of arthritis
* Osteoporosis
* History of patellofemoral symptoms
* Active non-arthritic knee disease
* Knee surgery
* Use of cane or walking aid
* Unstable heart condition
* Neurological conditions
* Skin allergy to medical tape
* Hip or ankle injuries in past 3 months
* Any injuries that would prohibit participation in yoga
* Ipsilateral hip or ankle conditions
* Currently receiving cancer treatment
* Currently pregnant
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers

The use of a suction blister apparatus has facilitated study of the immunologic capacity of human epidermal cells. We have been able to prepare purified populations of these cells after blister formation. Specifically, using the blister tops, we are able to enrich for epidermal Langerhans cells which are very potent stimulators in antigen presenting assays. Thus, this normal volunteer study provides an important source of fresh epidermal tissue from which we can study normal epidermal Langerhans cell function. In addition, we have recently used blister roofs in important experimental models of HIV-1 transmission. There is no other method available for assessing the biologic function of freshly isolated Langerhans cells without altering their milieu. It is a very safe and effective way to obtain human epidermal samples.

The use of a suction blister apparatus has facilitated study of the immunologic capacity of human epidermal cells. We have been able to prepare purified populations of these cells after blister formation. Specifically, using the blister tops, we are able to enrich for epidermal Langerhans cells which are very potent stimulators in antigen presenting assays. Thus, this normal volunteer study provides an important source of fresh epidermal tissue from which we can study normal epidermal Langerhans cell function. In addition, we have recently used blister roofs in important experimental models of HIV-1 transmission. There is no other method available for assessing the biologic function of freshly isolated Langerhans cells without altering their milieu. It is a very safe and effective way to obtain human epidermal samples.

Eligibility Criteria:
INCLUSION CRITERIA

Patients with urticaria of all types, blistering diseases, inflammatory dermatoses and neoplastic skin diseases.

Patients 18 years of age or older.

No pregnant women.